TRAF6在食管癌中的表达及临床意义

Expression and clinical significance of TRAF6 in patients with esophageal cancer

目的:探讨肿瘤坏死因子受体相关因子6(TRAF6)在人食管癌组织中的表达及临床意义。方法:收集2005年1月至2010年01月在本院接受首次手术治疗的食管癌患者78例,通过免疫组织化学方法检测TRAF6蛋白在食管癌及其癌旁组织中的表达,并探讨TRAF6的表达量与临床病理特征和患者预后的相关性。结果:TRAF6在食管癌组织中阳性表达率为71.79%,明显高于癌旁正常组织中的10.26%;进一步研究发现TRAF6的表达量与食管癌患者的性别、年龄、分化程度及肿瘤大小无关(P>0.05),与临床分期和淋巴结转移呈正相关(P<0.05),进一步研究发现TRAF6的表达量与患者的五年生存率密切相关,高表达TRAF6蛋白的患者五年生存率显著低于低表达的患者(P=0.011)。结论:TRAF6在食管癌组织中的表达量明显升高,并与患者的预后密切相关。

Objective： To examine the expression of TRAF6 in esophageal organization from protein level and analyze the correlations between TRAF6 expression and clinical features. Methods： Seventy-eight patients with esophageal adenocarcinoma who were admitted to the Department of Oncology,Henan Province Hospital of TCM from January 2005 and January 2010 were finally eligible for present study and the corresponding esophageal normal tissues and clinical data were collected. All the specimens were confirmed by pathology for esophageal squamous cell carcinoma or esophageal normal tissues. The expression of TRAF6 in the tissue samples was detected by immunohistochemistry. The correlation between the TRAF6 expression and clinical characteristics of patients was analyzed. Results： The positive expression rate of TRAF6 in esophageal cancer organizations and normal esophageal mucosal tissues were 71. 79% and 10. 26%,respectively. The positive expression rate of TRAF6 in esophageal cancer were significantly higher than those in normal esophageal mucosal tissue（ P 〈0. 05）. The positive expression rate of TRAF6 in esophageal cancer organizations has nothing to do with the age,sex,tumor differentiation degree and size（ P 〉0. 05）,but with lymph node metastasis and clinical stage（ P 〈0. 05）. Patients with positive TRAF6 expression had significantly lower five-year survival rate than those with tumors having positive TAK1 expression. Conclusion： TRAF6 may play an important role in the pathology and development of squamous cell carcinoma,and could be an important therapeutic target in the treatment of esophageal cancer.